Pre-Approval Inventory

Product inventory manufactured prior to regulatory approval, which is typically expensed immediately rather than capitalized.

Pre-approval inventory refers to product batches manufactured by a pharmaceutical, biotechnology, or medical device company before receiving official regulatory clearance (such as FDA approval). Under standard accounting guidelines, because commercialization is highly uncertain, the costs associated with manufacturing these goods cannot be capitalized as assets on the balance sheet. Instead, they must be expensed immediately, typically under research and development (R&D) or pre-launch manufacturing expenses. If the product subsequently wins regulatory approval, the company can sell this previously expensed inventory to customers. Because the cash costs of manufacturing were already recognized in prior periods, the cost of goods sold (COGS) associated with these initial sales is virtually zero. This creates a temporary, artificially high gross margin during the initial quarters of the product launch. Investors must carefully track pre-approval inventory to avoid misinterpreting a company's long-term profitability. Once the zero-cost inventory is fully depleted, COGS will rise to reflect the actual ongoing cost of manufacturing new batches, causing gross margins to normalize downward. Analysts typically adjust their financial models to strip out this temporary benefit and assess the true underlying unit economics of the product.

Company A expenses $15 million in manufacturing costs for a drug candidate as R&D. After receiving FDA approval, Company A launches the drug and sells this pre-approval inventory for $20 million in revenue. Because the manufacturing costs were already expensed in prior years, the recorded COGS for these sales is $0, resulting in a temporary gross margin of 100% ($20 million gross profit / $20 million revenue). Once this inventory is depleted, new batches cost $3 million to make, normalizing the ongoing gross margin to 85% (($20 million - $3 million) / $20 million).